PMID- 33779768
OWN - NLM
STAT- MEDLINE
DCOM- 20211104
LR  - 20221207
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 77
IP  - 5
DP  - 2021 May
TI  - The impacts of race and regimens on the efficacy and safety of paclitaxel and 
      platinum combination treatment for patients with advanced non-small cell lung 
      cancer.
PG  - 685-695
LID - 10.1007/s00228-021-03129-6 [doi]
AB  - PURPOSE: Paclitaxel-platinum chemotherapy is the first-line treatment for 
      advanced non-small cell lung cancer (NSCLC) patients. This study quantitatively 
      evaluated the factors influencing the efficacy and safety of the 
      paclitaxel-platinum regimen to provide the necessary reference for the 
      development of clinical practice and clinical trials. METHODS: A literature 
      search was performed using public databases. The parametric survival function was 
      used to analyze the overall survival (OS) time course of patients treated with 
      the paclitaxel-platinum regimen. The random effects model in the single-arm 
      meta-analysis was used to analyze the objective response rate (ORR) and the 
      incidence of grade 3-4 adverse events (AEs) under the predefined subgroups 
      according to race and the regimen. RESULTS: A total of 31 studies consisting of 
      3365 participants were included in the analysis. Race was the most important 
      determinant of efficacy and safety in the paclitaxel-platinum regimen, with the 
      median survival time and ORR in East Asians and non-East Asians being 12.2 months 
      (95% CI: 10.5-14.4 months) and 37% (95% CI: 32-41%) and 8.4 months (95% CI: 
      6.5-11.0 months) and 28% (95% CI: 25-32%), respectively. The incidence of grade 
      3-4 AEs such as leukopenia and neutropenia was about three times higher in East 
      Asians compared to non-East Asians. CONCLUSIONS: The efficacy and safety of the 
      paclitaxel-platinum regimen can vary between East Asian and non-East Asian 
      populations and between different treatment schedules. The results of this study 
      can provide a reliable and precise external control for the future evaluation of 
      new treatment options for advanced NSCLC.
FAU - Zhao, Chenyang
AU  - Zhao C
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Wang, Fengli
AU  - Wang F
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Huang, Jihan
AU  - Huang J
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Lv, Yinghua
AU  - Lv Y
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Yin, Fang
AU  - Yin F
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Liu, Hongxia
AU  - Liu H
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Zheng, Qingshan
AU  - Zheng Q
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China. qingshan.zheng@drugchina.net.
FAU - Li, Lujin
AU  - Li L
AD  - Center for Drug Clinical Evaluation, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China. lilujin666@163.com.
LA  - eng
GR  - 17401970900/Shanghai S&T Innovation Plan/
GR  - 2018ZX09734005/National Major Science and Technology Projects of China/
GR  - 2018ZX09711001-009-011/National Major Science and Technology Projects of China/
GR  - 2018ZX09731016/National Major Science and Technology Projects of China/
GR  - 2017ZX09304003/National Major Science and Technology Projects of China/
GR  - 2018ZX10303501/National Major Science and Technology Projects of China/
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210329
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 49DFR088MY (Platinum)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects/*therapeutic use
MH  - *Asian People
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Monte Carlo Method
MH  - Neoplasm Staging
MH  - Paclitaxel/therapeutic use
MH  - Platinum/therapeutic use
MH  - Survival Analysis
OTO - NOTNLM
OT  - Advanced NSCLC
OT  - Modeling and simulation
OT  - Overall survival
OT  - Paclitaxel
OT  - Platinum
EDAT- 2021/03/30 06:00
MHDA- 2021/11/05 06:00
CRDT- 2021/03/29 13:34
PHST- 2021/01/26 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/03/30 06:00 [pubmed]
PHST- 2021/11/05 06:00 [medline]
PHST- 2021/03/29 13:34 [entrez]
AID - 10.1007/s00228-021-03129-6 [pii]
AID - 10.1007/s00228-021-03129-6 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2021 May;77(5):685-695. doi: 10.1007/s00228-021-03129-6. 
      Epub 2021 Mar 29.